Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

se 3 studies (301, 302 and 303), at baseline and at weeks 2, 6 and 13. This OBPM data was pooled and analyzed according to a prospectively designed statistical plan, the objective of which was to evaluate the blood pressure profile of naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 500 mg bid and placebo, in a large OA population.

Both doses of naproxcinod showed a similar blood pressure profile to placebo, as indicated by one-sided 95% confidence intervals (CIs). Naproxen 500 mg bid raised systolic blood pressure (SBP) by 2.0 mmHg compared to placebo, in terms of the mean change between baseline and the average over weeks 2, 6 and 13. Further analyses on these pooled data are ongoing and NicOx plans to disclose more detailed results at leading medical conferences and in peer reviewed scientific publications during 2009 and 2010.

Two additional ABPM studies provided critical, complementary data to the phase 3 program

In November and December, NicOx announced the top-line results of the 111 and 112 clinical pharmacology studies in OA patients with controlled hypertension. These trials were designed to assess the 24-hour blood pressure profile of naproxcinod and two of the most widely used non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen and naproxen. The state of the art ABPM technique was used, providing critical, complementary data to the phase 3 OBPM data.

    - In the 111 study, 118 patients were randomized to receive naproxcinod
      or naproxen, with escalating doses every three weeks (375, 750 and
      1125 mg bid for naproxcinod, 250, 500 and 750 mg bid for naproxen).
      Over the whole study period, naproxcinod lowered SBP by 2.3 mmHg from
      baseline and naproxen raised it by 1.5 mmHg from baseline.

    - In the 112 study, 299 patients were randomized to receive naproxcinod
      375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen
      
'/>"/>
SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Ga. , Sept. 17, 2014  MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today the publication of another peer-reviewed clinical study. ... A Multi-center Randomized Controlled Clinical Trial Evaluating ... Amnion/Chorion Membrane Allografts and Multi-layer Compression Therapy vs. ...
(Date:9/17/2014)... September 17, 2014 A biodegradable ... microorganisms such as bacteria, fungi, and algae into ... methane, biomass, inorganic compounds, carbon dioxide, and humus ... customer base and improved costs, biodegradable polymers are ... viable alternative to conventional polymers. Primary factors that ...
(Date:9/17/2014)... JH Technologies announces the grand opening ... JH Technologies, a leader in sales and support of ... partnership with Leica Microsystems into the Southern California market. ... will be featured at the grand opening slated for ... is located within the JH Technologies office’s at 18025 ...
(Date:9/17/2014)... 2014 BioClinica®, Inc., a leading provider of ... three of its experts are speaking at the ... to be held September 28 to October 1 in ... also announced the innovative Compass technology, a ... trials acquired earlier this year, is up for the ...
Breaking Biology Technology:MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3
... NEW YORK, July 24 American Oriental,Bioengineering, Inc. (NYSE: ... release,second quarter 2008 financial results on Monday, August 11, ... a conference call at 5:00 pm ET on August ... Listeners may,access the call by dialing 1-800-599-9816 or 1-617-847-8705 ...
... SOUTH SAN FRANCISCO, Calif., July 24 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that it will hold ... results and provide a corporate update,including an update ... lead product candidate. Jerry McMahon, Ph.D., chairman and ...
... July 24 Sagent Pharmaceuticals, Inc.,a privately-held specialty ... for injection, USP, a semisynthetic,broad-spectrum, beta-lactam antibiotic. Sagent ... vials and 6g pharmacy bulk package vials. According ... the United States were,approximately $45.7 million., "Sagent ...
Cached Biology Technology:Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2
(Date:9/17/2014)... bags and their environmental impact recently scored a major ... ban on the bags, and Governor Jerry Brown is ... is not yielding without a fight, according to an ... weekly newsmagazine of the American Chemical Society. , Alexander ... anti-bag campaign logged its first small victory in 1990 ...
(Date:9/17/2014)... Copenhagen Centre for Social Evolution and Yale University offers ... weight and -length can partially predict the likelihood of ... and schizophrenia later in life. The study analyzed medical ... diagnoses for up to 30 years, and adjusted for ... published today in the Proceedings of the Royal ...
(Date:9/17/2014)... Informatics at IMIM (Hospital del Mar Medical Research Institute) ... recently published a study in eLife showing ... in the evolution of new proteins, some of which ... Ribosomes produce proteins from the instructions found in an ... is RNA containing information for the synthesis of proteins, ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Parts of genome without a known function may play a key role in the birth of new proteins 2
... treatment for stroke has taken a major step forward following ... The University of Manchester have shown in laboratory studies that ... injury and death. , The team, led by Professor Nancy ... of the first small trial of IL-1ra in patients, which ...
... of diseases , A team of international researchers ... 15 regulates inflammation, a finding with implications for ... disease, diabetes, obesity, Alzheimer's, and infections. The ... issue of Nature Genetics. , Investigators believe this ...
... Hopkins researcher, with colleagues in Sweden and at the ... view of cancer as a group of diseases with ... alterations within a cell's nuclear DNA may have to ... January issue of Nature Reviews Genetics, available online Dec. ...
Cached Biology News:Stroke treatment a step closer after trial 2Scientists pinpoint inflammation gene 2Scientists pinpoint inflammation gene 3Scientists pinpoint inflammation gene 4New view of cancer: 'Epigenetic' changes come before mutations 2
Schneider's Drosophila Medium is formulated for the expression of heterologous proteins in Drosophila S2 cells....
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Biology Products: